Protecting health in new trade agreements (Nina Renshaw, European Public Health Alliance)

 

Nina Renshaw, Secretary-General, the European Public Health Alliance

With the public debate around Brexit focusing mainly on its economic and legal consequences, public health concerns are in danger of falling by the wayside. There is a need to bring health to the forefront of the Brexit process.

The Article 50 negotiations to withdraw the UK from the EU may not be the toughest talks that the UK government must hold. As the Financial Times has pointed out, post-Brexit the UK will need to negotiate at least 759 treaties with 168 countries to maintain the UK’s current international relationships. Many of these concern ‘non-tariff barriers’ – such as safety or environmental standards – and clauses seeking to protect companies investing abroad. Indeed, 295 of these treaties are international trade deals struck by the EU on behalf of all member states. A further 202 determine the rules of regulatory cooperation between countries, for example mutual recognition of product standards. The rest are sectoral agreements, for example on movement of goods and cross-border services in agriculture, transport and nuclear energy.

Both directly and indirectly, many of these treaties have an impact on the health of people in the UK. Some of these are in surprising fields, which the UK’s fledgling trade negotiators may not have yet considered.

Potential loss of protections without debate

An immediate danger for public health lies in the European Union (Withdrawal) Bill, under which the body of EU legislation – including valuable protections for health, consumers, the environment, workers and safety – is effectively being copied and pasted into the UK statute book. There is concern among civil society organisations across a number of sectors that EU protections could potentially be quietly dropped by the government without parliamentary debate – using the so-called ‘Henry VIII’ causes.

Many commentators in the UK, especially leading Brexiteers, are notorious for complaining about ‘red tape’ and over-regulation as a result of EU Council negotiations. Health and safety protections – not only those in the workplace but also safety standards for consumer goods and standards for clean air and water – may be under threat. Civil society groups will need to be especially vigilant and monitor the retention of these protections through the transition processes.

Harmful goods

More generally, huge effort will be needed when negotiating future international trade deals if public health is to become a ‘red line’ issue. It certainly has not been for the EU and was barely on the European Commission’s radar until the Transatlantic Trade and Investment Partnership (TTIP) negotiations with the US. In terms of the (relatively limited) body of current EU legislation that protects public health (eg the Tobacco Products Directive and REACH legislation on harmful chemicals or food safety standards), the UK may be more vulnerable to the power of industry lobbies when it is negotiating alone. It may even be tempted to shift to a low-regulation environment as a strategy for competitive advantage, as David Davis has publicly hinted.

During the EU’s international trade negotiations, health groups including the European Public Health Alliance (EPHA) felt the need to take EU trade negotiators back to basics, to explain how increased availability and cheaper prices for some categories of goods would have an overall negative economic impact through imposed health harm – tobacco and junk foods were the most obvious goods here.

In the context of the UK’s new trading relationships, the same awareness-raising effort will be needed among the untested UK negotiators to encourage different approaches to health-harmful and health-promoting goods. A look at the lobby groups most vocal in their support of the EU–Canada and EU–US trade deals reveals the sectors that think they have most to gain – spirits, meat, pesticides and chemicals – and should ring alarm bells for anyone concerned with public health.

Investment protection and dispute settlement procedures

One element of international trade deals that poses a very severe threat to public health is the inclusion of so-called ISDS clauses (investor–state dispute settlement). Public uproar over ISDS clauses and their potential for abuse by multinational corporations to block health-protecting legislation persuaded the EU to drop the proposal in trade negotiations with the US. The EU’s recent attempt to reform the system by rebranding it as an Investment Court System (and building on this via a Multilateral Investment Court) does not address the fundamental flaws of the arbitration system. But for the UK’s new deals, ISDS will likely be back on the table – unless the government has the foresight to propose an alternative.

These ISDS clauses have increasingly featured in trade negotiations, after previously being largely confined to more obscure bilateral investment treaties between developed and developing countries. They are also being used more and more around the world by corporations – including, notably, the big tobacco companies – to sue governments intending to introduce legislation that these corporations claim will harm their investments. Examples include Philip Morris claiming billions in compensation for lost revenues from the Uruguayan and Australian governments for the introduction of plain packaging. Both cases were lost and both countries went ahead with the schemes, but not until lengthy legal challenges had been resolved.

The real impact of the cases, though, was as a threat to other governments, to back off plans for smoke-free policies for fear of being sued. Given that the UK is home to many of the world’s biggest tobacco companies – as well as alcohol and chemicals companies – bet they’re already lobbying hard for ISDS to be included across the board. This is a strategy to undermine hard-won progress achieved under the UN Framework Convention on Tobacco Control, which strengthened governments’ hands against the might of large producers of health-harming products.

Medicines and medical devices

The Euratom Treaty, that the UK has announced it plans to leave, provides a small insight into the importance of international treaties to our daily lives and the potential negative impact on health of a ‘no deal’ Brexit. It regulates the trade and transport of nuclear fuel rods, as well as radioisotopes used in radiotherapy and materials used in diagnostics. All medical isotopes used in the UK are imported, mostly from the Netherlands, so new agreements need to be struck quickly to secure their continued supply. Despite some media attention during 2017, this issue has yet to be tackled by negotiators.

New trade deals will be needed in fields with the most obvious relevance for health and care, including medicines and medical devices. The UK currently has direct access to new medical innovations approved by the European Medicines Agency (EMA). But one of the few certainties of Brexit is that the EMA will have to vacate its current headquarters in London for a new EU home (in Amsterdam). How the UK will engage with the EMA approvals process going forward is a subject for the second phase of negotiations on the future relationship with the EU. The continuation of the relationship between the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the EMA is of vital importance to patients on both sides of the channel, as the MHRA currently covers a disproportionate share of the EMA’s workload. In a ‘no deal’ scenario the EMA would need to seamlessly replace the expertise provided by the MHRA without any disruption to medicines approvals that would cause delays to patients in both the UK and the EU.

Any silver lining?

Admittedly, EU policy is far from being consistent in putting health first in many markets. Examples include the recent failure to limit advertising of health-harming food and drinks to children through the recently reviewed Audiovisual Media Services Directive, and alcohol, for which health measures are often challenged on the grounds they disrupt the flow of European trade or contradict agricultural subsidies. Indeed, the Scottish Government had to dramatically delay its plan to introduce minimum unit pricing for alcohol as a health protection measure. This was because the Scotch Whisky Association (supported by the European spirits and wine lobbies) challenged the decision all the way to the European Court of Justice, claiming it would disrupt the internal EU market. Similarly, the EU lacks a coordinated strategy on tackling non-communicable diseases such as cardiovascular disease, cancer, respiratory diseases and diabetes, as well as mental health conditions.

The UK remains a world leader in public health thanks to a strong tradition built over centuries in academia, research, the media (The Lancet and the BMJ) and civil society, which has given rise to a strong institutional framework in government. More recently, Edinburgh and Cardiff – empowered by devolution – have taken on a leading role, so it is essential to think beyond Whitehall and Westminster. This longstanding strength in the UK compares very favourably with other countries and could be converted into a competitive advantage: Brexit could be an opportunity to build further on this tradition of leadership.

Post-Brexit, the UK could move faster with a raft of public health policies, including minimum unit pricing right across the UK; banning trans fats, controversial and potentially carcinogenic herbicides and hormone-disrupting chemicals; and taking a much tougher approach to high-sugar products. But that, of course, depends on domestic political will. The potential post-Brexit policy vacuum has unleashed a wave of lobbying activity, especially among industry players, that the health community will need to match. It will be necessary to evidence why progress is needed on health promotion and disease prevention and which policies can effectively contribute, but a new level of public mobilisation will also be needed to counter the prevailing deregulatory agenda.

How should the UK approach trade policy?

Trade policy has recently and rapidly become an unavoidable focus of health-in-all-policies approaches to decision making. In trade, the largest markets set the rules: UK companies will still have to comply with EU standards if they want to export to the EU. Brexit means (for better or worse) that for the foreseeable future, new trade deals will need close attention from health campaigners and civil society in the UK and internationally. Health experts must act quickly to become valued interlocutors for trade negotiators on both sides of Brexit. The confluence of Brexit and trade policy is not only of vital importance for patients, the research community, health workers and employers but for the whole of society: health protections and with them the future sustainability of the NHS are at stake.


*** Such provisions are so named from the Statute of Proclamations 1539, which gave King Henry VIII power to legislate by proclamation. This enables primary legislation to be amended or repealed by subordinate legislation with or without further parliamentary scrutiny.

Previous Next